Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
LN-229 is an epithelial-like cell line, originally isolated in 1979 from the right frontal parieto-occipital cortex of a 60-year-old Caucasian female diagnosed with glioblastoma. These cells possess tumorigenic capabilities, forming tumors in nude mice. LN-229 cells harbor a mutated p53 (TP53) and may exhibit homozygous deletions in the p16 and p14ARF tumor suppressor genes, while their PTEN gene remains wild-type. Notably, stimulation of LN-229 cells with Fas ligand induces apoptotic cell death within a short 16-hour timeframe, and they display dose-dependent sensitivity to puromycin-induced apoptosis. Bcl-2 provides substantial protection against Fas ligand-induced cell death but offers only modest safeguarding against puromycin-induced apoptosis.
Why choose LN-299 from AcceGen?
LN-229 cells from AcceGen boast exceptional features, including high viability and quality, having been meticulously incubated under optimal conditions. These cells are provided sterile and have undergone rigorous quality control, ensuring they are free from bacteria, yeast, mycoplasma, HIV, and HBV, making them a reliable choice for various research applications.
| Product Code | LN 229; LN229; LNT-229 |
| Species | Human |
| Cat.No | ABC-TC498S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Glioblastoma |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
LN-229 represents a significant asset in the realm of neuroscience research. Its applications extend to the in-depth exploration of the intricate mechanisms governing cell proliferation and the progression of glioblastoma, thereby facilitating the identification of promising therapeutic targets. Furthermore, this cell line plays a pivotal role in the development of advanced radiotherapy strategies for glioblastoma treatment. Its use in evaluating the sensitivity of tumor responses to radiotherapy offers a scientific framework for enhancing our comprehension of this intricate neuro-oncological landscape and the refinement of treatment modalities.
